Resistance to activated protein C due to a factor V gene mutation: The most common inherited risk factor of thrombosis

Trends in Cardiovascular Medicine

Volumn 6, Issue 2, 1996, Pages 45-53

  Zöller, Bengt ^a   Holm, Johan ^a   Dahlbäck, Björn ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; PROTEIN C; PROTEIN S;

AMINO ACID SUBSTITUTION; ANTICOAGULATION; BLOOD CLOTTING; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC DISORDER; GENETIC RISK; HYPERCOAGULABILITY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK FACTOR; SHORT SURVEY; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS;

EID: 4243738904     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/1050-1738(95)00130-1     Document Type: Short Survey

References (89)

1. Aparicio C, Dahlbäck B: 1995. Molecular mechanisms of activated protein C resistance based on studies using purified FV: Q506. Biochemistry J (in press).
2. Arruda VR, Annichinobizzacchi JM, Costa FF, Reitsma PH: 1995. Factor V Leiden (FVQ 506) is common in a Brazilian population. Am J Hematol 49:242-243.
3. Bauer KA: 1995. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost 74:94-100.
4. Beauchamp NJ, Daly ME, Cooper PC, Preston FE, Peake IR: 1994. Rapid two-stage PCR for detecting factor V G1591A mutation. Lancet 344:694-695.
5. Bertina RM, Koeleman BPC, Koster T, et al.: 1994. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64-67.
6. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP: 1995. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 74:449-453.
7. Bovill EG, Bauer KA, Dickermann JD, Callas P, West B: 1989. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 73:712-717.
8. Broekmans AW, Conard J: 1988. Hereditary protein C deficiency. In Bertina RM, ed. Protein C and Related Proteins. Edinburgh, Churchill Livingstone, pp 160-181.
9. Cadroy Y, Sié P, Boneu B: 1994. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 83:2008-2009.
10. Catto A, Carter A, Ireland H, et al.: 1995. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 15:783-785.
11. Comp PC, Esmon CT: 1984. Recurrent thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 311: 1525-1528.
12. Conard J, Trossaërt M, Horellou MH, Elalamy I, Cheloufi L, Samama MM: 1995. Risk of venous thrombosis in 51 women with resistance to activated protein C associated with factor V Leiden [abst]. Thromb Haemost 73:1375.
13. Coon WW, Willis PW, Keller JB: 1973. Venous thromboembolism and other venous disease in the Tecumseh Community health study. Circulation 48:839-846.
14. Cushman M, Bhushan F, Bovill E, Tracy R: 1994. Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemost 72:647.
15. Dahlbäck B: 1995. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 77:1-43.
16. Dahlbäck B, Hildebrand B: 1994. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 81:1396-1400.
17. Dahlbäck B, Carlsson M, Svensson PJ: 1993. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90:1004-1008.
18. Davie EW: 1995. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 74:1-6.
19. Demarmels Biasiutti F, Merlo C, Furlan M, Sulzer I, Binder BR, Lämmle B: 1995. Prevalence of APC resistance in 134 survivors of myocardial infarction [abst]. Thromb Haemost 73:1125.
20. Denninger MH, Beldjord K, Durand F, Denié C, Valla D, Guillin MC: 1995. Budd-Chiari syndrome and factor V Leiden mutation. Lancet 345:525-526.
21. De Ronde H, Bertina RM: 1994. Laboratory diagnosis of APC resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 72:880-886.
22. De Stefano V, Mastrangelo S, Paciaroni K, et al.: 1995. Prevalence of venous thrombosis in pregnant women with APC resistance: a retrospective study [abst]. Thromb Haemost 73:1375.
23. Dexter L: 1973. President's address: the chair and venous thrombosis. Trans Am Clin Climatol Assoc 84:1-15.
24. Emmerich J, Poirier O, Evans A, et al.: 1995. Myocardial infarction, Arg506 to Gln factor V mutation, and activated protein C resistance. Lancet 345:321.
25. Eritsland J, Gjonnes G, Sandset PM, Seljeflot I, Arnesen H: 1995. Activated protein C resistance and graft occlusion after coronary artery bypass surgery. Thromb Res 79:223-226.
26. Esmon 1992: The protein C anticoagulant pathway. Arterioscler Thromb 12:135-145.
27. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM: 1993. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 70:1067-1071.
28. Fauno P, Ravn HB, Lassen JF, Lund ED, Jensen ED: 1995. Association between activated protein C resistance and postoperative deep vein thrombosis [abst]. Thromb Haemost 73:1371.
29. Forsyth PD, Dolan G: 1995. Activated protein C resistance in cases of cerebral infarction. Lancet 345:795.
30. Furie B, Furie BC: 1988. The molecular basis of blood coagulation. Cell 53:505-518.
31. Gandrille S, Greengard JS, Alhenc-Gelas M, et al.: 1995. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 86:219-224.
32. Gjöres JE: 1956. The incidence of venous thrombosis and its sequelae in certain districts in Sweden. Acta Chir Scand (Suppl) 206:1-88.
33. Goldhaber SZ: 1994. Epidemiology of pulmonary embolism and deep vein thrombosis. In Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. Edinburgh, Churchill Livingstone, pp 1327-1333.
34. Greengard JS, Eichinger S, Griffin JH, Bauer KA: 1994a. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg→Gln mutation in the gene for factor V. N Engl J Med 331:1559-1562.
35. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt BL: 1994b. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 343:1362-1363.
36. Griffin JH, Evatt BL, Zimmerman TS, Kleiss AJ, Wideman C: 1981. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68:1370-1373.
37. Griffin JH, Evatt BL, Wideman C, Fernandez JA: 1993. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 82:1989-1993.
38. Halbmayer WM, Haushofer A, Schön R, Fischer M: 1994. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinol 5:51-57.
39. Hallam PJ, Millar DS, Krawczak M, Kakkar VV, Cooper DN: 1995. Population differences in the frequency of the factor V Leiden variant among people with clinically symptomatic protein c deficiency. J Med Genet 32:543-545.
40. Heeb MJ, Kojima Y, Greengard JS, Griffin JH: 1995. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood 85: 3405-3411.
41. Heijboer H, Brandjes D, Büller HR, Sturk A, ten Cate JW: 1990. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 323:1512-1516.
42. Heinrich J, Schulte H, Funke H, Schönfeld R, Köhler E, Assmann G: 1995. Frequency of point mutation in factor V gene (1,691 G/A), which is associated with resistance to activated protein C, in coronary artery disease patients [abst]. Thromb Haemost 73:1125.
43. Hellgren M, Svensson PJ, Dahlbäck B: 1995. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol (in press).
44. Holm J, Zöller B, Svensson PJ, Berntorp E, Erhardt L, Dahlbäck B: 1994. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 344: 952-953.
45. Holm J, Zöller B, Svensson PJ, Berntorp E, Erhardt L, Dahlbäck B: 1996. Prevalence of factor V gene mutation among myocardial infarction patients and healthy controls higher in Sweden than in other countries. J Int Med (in press).
46. Hopmeier P, Krugluger W: 1995. Factor V Leiden and thrombophilia. N Engl J Med 332:1381-1382.
47. Ireland H, Bayston T, Chowdhury V, et al.: 1995. Factor V Leiden as an independent risk factor for thrombosis in antithrombin deficiency type II: heparin binding site [abst]. Thromb Haemost 73:1361.
48. Kalafatis M, Rand MD, Mann KG: 1994. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 269:31,869-31,880.
49. Kalafatis M, Bertina RM, Rand MD, Mann KG: 1995. Characterization of the molecular defect in factor VR506Q. J Biol Chem 270:4053-4057.
50. Kambayashi J, Fujimura H, Kawasaki T, et al.: 1995. The incidence of activated protein C resistance among patients with deep vein thrombosis and healthy subjects in Osaka. Thromb Res 79:227-229.
51. Kane WH, Davie EW: 1988. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 71:539-555.
52. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM: 1994. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 84:1031-1035.
53. Kontula K, Ylikorkala A, Miettinen H, et al.: 1995. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 73:558-560.
54. Koster T, Rosendaal FR, de Ronde F, Briët E, Vandenbroucke JP, Bertina RM: 1993. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet 342:1503-1506.
55. Levoir D, Emmerich J, Alhenc-Gelas M, et al.: 1995. Portal vein thrombosis and factor V Arg 506 to Gln mutation. Thromb Haemost 73:550-551.
56. Mahmoud AEA, Wilde JT, Elias E: 1995. Budd-Chiari syndrome and factor V Leiden mutation. Lancet 345:526.
57. Majerus PW: 1994. Bad blood by mutation. Nature 369:14-15.
58. Malm J, Laurell M, Nilsson IM, Dahlbäck B: 1992. Thromboembolic disease: critical evaluation of laboratory investigation. Thromb Haemost 68:7-13.
59. Marlar RA, Neumann A: 1990. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 16:299-309.
60. Miletich JP, Sherman L, Broze GJ Jr: 1987. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 317:991-996.
61. März W, Seydewitz H, Winkelmann B, Chen M, Nauck M: 1995. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 345:526-527.
62. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG: 1993. Inherited predisposition to thrombosis. Cell 72:477-480.
63. Monreal M, Ruiz J, Salvador R, Morera J, Arias A: 1989. Recurrent pulmonary embolism: a prospective study. Chest 95:976-979.
64. Nemerson Y: 1988. Tissue factor and hemostasis. Blood 71:1-8.
65. Pabinger I, Mustafa S, Rintelen C, Kyrle PA, Lechner K, Mannhalter C: 1995. Factor V (FV) Leiden mutation (APC resistance) increases the risk for venous thromboembolism in patients with a gene defect of the protein C (PC) or protein S (PS) gene [abst]. Thromb Haemost 73:1361.
66. Pötzsch B, Rehling T, Knedla A, Müller-Berghaus G: 1995. APC resistance: factor V is not involved in proteolytic inactivation of factor VIII by activated protein C [abst]. Thromb Haemost 73:1121.
67. Radtke KP, Lane DA, Greengard JS, Ehrenforth S, Griffin JH: 1995. Combined hereditary APC resistance and ATIII type II deficiency associated with venous thrombosis [abst]. Thromb Haemost 73:1377.
68. Rees DC, Cox M, Clegg JB: 1995. World distribution of factor V Leiden. Lancet 346: 1133-1134.
69. Reitsma PH, Poort SR, Allaart CF, Briët E, Bertina RM: 1991. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. Blood 78:890-894.
70. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP: 1995. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332:912-917.
71. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: 1995. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85: 1504-1508.
72. Samani N, Lodwick D, Martin D, Kimber P: 1994. Resistance to activated protein C and risk of premature myocardial infarction. Lancet 344:1709-1710.
73. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH: 1984. Plasma protein S deficiency in familial thrombotic disease. Blood 64:1297-1300.
74. Seligsohn U, Berger A, Abend A, et al.: 1984 Homozygous protein C deficiency manifested by massive thrombosis in the newborn. N Engl J Med 310:559-562.
75. Shen L, Dahlbäck B: 1994. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem 269:18,735-18,738.
76. Sun X, Evatt BL, Griffin JH: 1994. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 83:3120-3125.
77. Svensson PJ, Dahlbäck B: 1994. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517-521.
78. Thiel F, Ehrenforth B, Zwinge B, Dingeldein E, Scharrer I: 1995. Relation between APC resistance and juvenile stroke [abst]. Thromb Haemost 73:1401.
79. Van Bockxmeer FM, Baker RI, Taylor RR: 1995. Premature ischaemic heart disease and the gene for coagulation factor V. Nat Med 1:185.
80. Van Boven HH, Reitsma PH, Rosendaal FR, et al.: 1995. Interaction of factor V Leiden with inherited antithrombin deficiency. [abst] Thromb Haemost 73: 1256.
81. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR: 1994. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344: 1453-1457.
82. Vàradi K, Rosing J, Tans G, Schwarz HP: 1995. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII. Thromb Haemost 73:730-731.
83. Viigimaa M, Saareoja Y: 1995. Prospective study on activates protein C resistance in patients with acute myocardial infarction [abst]. Thromb Haemost 73:1374.
84. Voorberg J, Roelse J, Koopman R, et al.: 1994. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet 343:1535-1536.
85. Zöller B, Dahlbäck B: 1994. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 343:1536-1538.
86. Zöller B, Svensson PJ, He X, Dahlbäck B: 1994. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 94:2521-2524.
87. Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B: 1995a. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 85:3518-3523.
88. Zöller B, He X, Dahlbäck B: 1995b. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost 73:743-745.
89. Zöller B, Holm J, Svensson PJ, Dahlbäck B: 1996. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous Arg 506 to Gln mutation in the factor V gene (APC resistance) and/or inherited protein S deficiency. Thromb Haemost (in press).